SEC Form 4 · accession 0001688199-26-000006
Dianthus Therapeutics, Inc. /DE/ · DNTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Simon Read
Director
Period of report
Aug 19, 2026
Accepted (ET)
Aug 19, 2026 · 6:02 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001690585
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 19, 2026 | M | 2,778 | $18.36 | A | 2,778 | D | |
| Common StockF2 | Aug 19, 2026 | S | 2,778 | $117.55 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $18.36 | Aug 19, 2026 | M | 2,778 | D | — | May 22, 2035 | Common Stock | 2,778 | 19,445 | D |
Explanation of responses
- F1The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on May 8, 2026.
- F2The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $117.01 to $117.66, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The shares of common stock underlying this stock option award vest as to one-third of the shares subject to the option on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continued service to the Issuer on each such vesting date.